BUSINESS SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

BUSINESS SEGMENT INFORMATION

The Company's DIS business provides insights through clinical testing and related services to patients, physicians, hospitals, ACOs, IDNs, health plans, employers and others. The Company is the world's leading provider of diagnostic information services, which includes providing clinical testing services such as routine (including drugs-of-abuse) testing, gene-based and esoteric testing, and anatomic pathology services, as well as related services and insights. The DIS business accounted for greater than 90% of net revenues from continuing operations in 2015, 2014 and 2013.

All other operating segments include the Company's DS businesses, which consists of its risk assessment services, clinical trials testing, diagnostic products and healthcare information technology businesses (see Note 6 regarding the contribution of the clinical trials testing business to a newly formed joint venture effective July 1, 2015 and non-core assets held for sale). The Company's DS businesses offer a variety of solutions for life insurers, healthcare providers and others.

During 2015, the Company acquired certain operations of MemorialCare and Superior Mobile Medics (see Note 5). MemorialCare is included in the Company's DIS business. Superior Mobile Medics is included in all other operating segments.

During 2014, the Company acquired Solstas, Summit Health and Steward which are included in the Company's DIS business.

During 2013, the Company acquired certain operations of UMass, ATN, Dignity and ConVerge which are included in the Company's DIS business. In addition, the Company completed the sale of Enterix in the third quarter of 2013, which is included in all other operating segments.

On April 19, 2006, the Company decided to discontinue NID’s operations. The Company completed the sale of HemoCue in the second quarter of 2013. The results of operations for NID and HemoCue have been classified as discontinued operations for all periods presented (see Note 18).

At December 31, 2015, substantially all of the Company’s services are provided within the United States, and substantially all of the Company’s assets are located within the United States.

The following table is a summary of segment information for the years ended December 31, 2015, 2014 and 2013. Segment asset information is not presented since it is not used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets, other operating income and expenses net of certain general corporate activity costs that are allocated to the DIS and DS businesses, and the third quarter of 2015 pre-tax gain on contribution of business to joint venture (see Note 6), the third quarter of 2013 pre-tax gain on the sale of the ibrutinib royalty rights and the pre-tax loss on the sale of Enterix. The accounting policies of the segments are the same as those of the Company as set forth in Note 2.

	2015			2014			2013
Net revenues:
DIS business	$	6,965		$	6,873		$	6,587
All other operating segments	528			562			559
Total net revenues	$	7,493		$	7,435		$	7,146
Operating earnings (loss):
DIS business	$	1,118		$	1,068		$	1,201
All other operating segments	110			94			76
General corporate activities	171			(179		)	198
Total operating income	1,399			983			1,475
Non-operating expenses, net	(296		)	(160		)	(151		)
Income from continuing operations before income taxes and equity in earnings of equity method investees	1,103			823			1,324
Income tax expense	(373		)	(262		)	(500		)
Equity in earnings of equity method investees, net of taxes	23			26			24
Income from continuing operations	753			587			848
Income from discontinued operations, net of taxes	—			5			35
Net income	753			592			883
Less: Net income attributable to noncontrolling interests	44			36			34
Net income attributable to Quest Diagnostics	$	709		$	556		$	849

	2015		2014		2013
Depreciation and amortization:
DIS business	$	212	$	206	$	189
All other operating segments	10		13		12
General corporate	82		95		82
Total depreciation and amortization	$	304	$	314	$	283
Capital expenditures:
DIS business	$	243	$	283	$	196
All other operating segments	16		17		26
General corporate	4		8		9
Total capital expenditures	$	263	$	308	$	231